High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

Duchenne muscular dystrophy (DMD) treatment ifetroban led to improvements in measures of heart function in a Phase 2 clinical ...

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

The FIGHT DMD trial (NCT03340675), is a 12-month, double-blind, randomized, placebo-controlled study evaluating ifetroban, an oral thromboxane receptor antagonist. The trial enrolled 41 DMD ...